Cellogen Therapeutics

Cellogen Therapeutics is an Indian biotechnology company focused on developing next-generation cell and gene therapies for cancers, blood disorders, and inherited diseases. Established in 2021 and headquartered in Noida, Uttar Pradesh, the company aims to make advanced regenerative medicines more affordable and accessible through indigenous research and manufacturing. Its mission is to develop patient-centric, long-lasting treatments that address the root causes of disease while significantly reducing the high cost of therapies that are currently available only in a few countries. By combining cellular engineering, gene editing, and immunotherapy, Cellogen Therapeutics is working to transform the treatment landscape for hematological malignancies, solid tumors, beta-thalassemia, sickle cell disease, and other genetic disorders. At the core of Cellogen's research is the development of advanced third- and fourth-generation CAR T-cell therapies, including innovative bi-specific CAR T-cell platforms designed to target multiple cancer antigens simultaneously. These therapies aim to improve treatment effectiveness while reducing the risk of cancer relapse caused by antigen escape. In parallel, the company is advancing gene-editing technologies, including CRISPR-based approaches and stem cell engineering, to develop potentially curative treatments for inherited blood disorders. Cellogen integrates computational biology, artificial intelligence, and precision medicine into its research pipeline to accelerate therapeutic discovery, optimize cell engineering, and enhance the safety and efficacy of next-generation treatments. To accelerate clinical translation, Cellogen Therapeutics collaborates with leading Indian research and healthcare institutions, including CSIR-IGIB, CSIR-IICB, DBT-Regional Centre for Biotechnology, and Christian Medical College (CMC), Vellore, for preclinical and clinical research. The company has also secured strategic funding from NATCO Pharma to support the development of its therapeutic pipeline. Alongside therapeutic innovation, Cellogen is strengthening India's cell and gene therapy ecosystem through indigenous manufacturing capabilities and its subsidiary, Cellogen Biotech, which produces critical reagents, plasmids, viral vectors, and other research materials required for advanced therapies. Through scientific innovation, strategic partnerships, and a commitment to affordable healthcare, Cellogen Therapeutics is positioning itself as a leading contributor to India's growing biotechnology sector and the global advancement of precision medicine.